Full Press Release Details
Biotech Inc.'s Research Collaborators to
Data on REOLYSIN Clinical Trials at ASCO Conference
CALGARY, AB, --- May 14, 2009
-Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today
that data from three clinical trials using REOLYSIN are scheduled to be
presented at the 2009 American Society of Clinical Oncology (ASCO) Annual
Meeting. The meeting will take place in Orlando, Florida May 29-June
2, 2009. The abstracts are available on the ASCO website today
poster presentations
Oncolytics Biotech Inc.
is a Calgary-based biotechnology company focused on the development of oncolytic
viruses as potential cancer therapeutics. Oncolytics' clinical
program includes a variety of Phase I/II and Phase II human trials using
REOLYSIN, its proprietary formulation of the human reovirus, alone and in
combination with radiation or chemotherapy. For further information
about Oncolytics, please visit www.oncolyticsbiotech.com
press release contains forward-looking statements, within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. Forward-looking
statements, including the implication of the materials to be presented at this
meeting with respect to REOLYSIN, the Company's expectations related to the
results of trials investigating delivery of REOLYSIN, and the Company's belief
as to the potential of REOLYSIN as a cancer therapeutic, involve known and
unknown risks and uncertainties, which could cause the Company's actual results
to differ materially from those in the forward-looking statements. Such risks
and uncertainties include, among others, the availability of funds and resources
to pursue research and development projects, the efficacy of REOLYSIN as a
cancer treatment, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize REOLYSIN,
uncertainties related to the research and development of pharmaceuticals,
uncertainties related to the regulatory process and general changes to the
economic environment. Investors should consult the Company's quarterly and
annual filings with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to the forward looking
statements. Investors are cautioned against placing undue reliance on
forward-looking statements. The Company does not undertake to update these
forward-looking statements, except as required by applicable laws.
FURTHER INFORMATION PLEASE CONTACT: